Agios Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Agios Pharmaceuticals CEO'su Brian Goff, Aug2022 tarihinde atandı, in görev süresi 2.25 yıldır. in toplam yıllık tazminatı $ 3.42M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.4% maaş ve 76.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.14% ine doğrudan sahiptir ve bu hisseler $ 4.37M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 7.6 yıldır.
Anahtar bilgiler
Brian Goff
İcra Kurulu Başkanı
US$3.4m
Toplam tazminat
| CEO maaş yüzdesi | 23.4% |
| CEO görev süresi | 2.3yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 7.6yrs |
Son yönetim güncellemeleri
Recent updates
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$674m |
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Tazminat ve Piyasa: Brian 'nin toplam tazminatı ($USD 3.42M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.59M ).
Tazminat ve Kazançlar: Brian 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Brian Goff (55 yo)
2.3yrs
Görev süresi
US$3,416,453
Tazminat
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. from June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.4m | |
| Chief Financial Officer | 2.2yrs | US$1.21m | 0.035% $ 1.1m | |
| Corporate Secretary & Chief Legal Officer | 2.8yrs | US$1.93m | 0.028% $ 869.8k | |
| Chief Medical Officer and Head of Research & Development | 3.2yrs | US$2.87m | 0.077% $ 2.4m | |
| Chief Commercial Officer | 1.8yrs | US$3.73m | 0.023% $ 733.3k | |
| Founder | no data | US$333.51k | Veri yok | |
| Founder | no data | Veri yok | Veri yok | |
| Founder | no data | Veri yok | Veri yok | |
| Founder | no data | Veri yok | Veri yok | |
| VP, Controller & Principal Accounting Officer | 3.3yrs | Veri yok | 0.0027% $ 84.4k | |
| Chief Technical Operations Officer | 7.4yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: AGIO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.4m | |
| Chair of the Board of Directors | 6.9yrs | US$447.25k | 0.25% $ 7.8m | |
| Independent Director | 1.4yrs | US$663.68k | 0.0035% $ 109.3k | |
| Member of Scientific Advisory Board | 8.3yrs | US$302.85k | Veri yok | |
| Member of Scientific Advisory Board | 15.8yrs | Veri yok | Veri yok | |
| Lead Independent Director | 9.9yrs | US$440.95k | 0.013% $ 418.3k | |
| Independent Director | 15.3yrs | US$417.25k | 0.83% $ 26.4m | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 16yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 3.8yrs | US$3.21m | Veri yok | |
| Independent Director | 2.3yrs | US$419.91k | 0.014% $ 442.6k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
7.6yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AGIO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.6 yıldır).